SeaStar Medical(NASDAQ) ICUCW

SeaStar Medical Holding Corporation is a biotechnology company based in Denver, Colorado, focused on developing innovative therapies to combat hyperinflammation and cytokine storms in critically ill patients. The company specializes in extracorporeal treatments that target immune effector cells, aiming to mitigate systemic inflammation and its damaging effects.

Products and Services

• Extracorporeal therapies for acute kidney injury in pediatric and adult patients
• Innovative solutions for cardiorenal syndrome in congestive heart failure cases
• Targeted treatments for myocardial stunning and hepatorenal syndrome

Growth Outlook

• Recent revenue growth from $183,000 to $495,000 in Q1 2026
• Strong focus on R&D with $2.34 million spent in Q1 2026
• Increasing cash reserves, ending Q1 2026 with $9.35 million

Financial Highlights

• Net income of -$3.52 million in Q1 2026, showing operational challenges
• Gross profit margin of 90.71% in Q1 2026, indicating strong product potential
• Current ratio of 2.73, reflecting solid liquidity position

SeaStar Medical Holding Corporation is positioned in a critical healthcare niche, addressing severe medical conditions that require innovative solutions. The company's focus on R&D and its growing product pipeline suggest potential for future growth. Despite recent financial challenges, the high gross profit margin indicates that the products may have strong market viability. The liquidity position, as evidenced by the current ratio, provides a buffer for ongoing operations and development. Investors may find the company's commitment to addressing significant health issues compelling as it navigates the complexities of the biotechnology sector.